Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab SC in active rheumatoid arthritis
NCT02046616Phase 3Completed
- Sponsor
- Roche
- Start
- May 2014
- Primary completion
- Sep 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Clinical Disease Activity Index at 12 weeks. Started May 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02046616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046616.